Results 131 to 140 of about 21,216 (279)

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis [PDF]

, 2015
Short communication[Abstract] Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving etravirine, according to the degree of liver fibrosis. Methods.
Bañón, S, Casado, José Luis, Castro-Iglesias, Ángeles, Mena, Álvaro, Moreno, A, Moreno, S, Pedreira, José D., Quereda, C   +7 more
core   +2 more sources

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity

European Journal of Medical Research, 2010
Background in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.
Ortu F, Weimer LE, Floridia M, Manconi PE   +3 more
doaj   +1 more source

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction [PDF]

, 2015
Mario Ostrowski, Erika Benko, Feng Yun Yue, Connie J. Kim, Sanja Huibner, Terry Lee, Joel Singer, Jim Pankovich, Oliver Laeyendecker, Rupert Kaul, Gabor Kandel, Colin Kovacs   +11 more
openalex   +1 more source

HIV Integrase Inhibitors Block Replication of Alpha-, Beta-, and Gammaherpesviruses [PDF]

, 2014
The catalytic site of the HIV integrase is contained within an RNase H-like fold, and numerous drugs have been developed that bind to this site and inhibit its activity.
Angelova, Magdalena, Bryant, Kevin F., Burke, Terrence R., Coen, Donald M., Dreyfus, David H., Gregory, Sean M., Knipe, David M., Yan, Zhipeng, Zhao, Xue Zhi   +8 more
core   +2 more sources

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA

Фармакоэкономика, 2015
The purpose of the work performed was assessment of cost efficiency of Raltegravir within the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group of protease inhibitors with adult patients with Type 1 HIV ...
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov   +4 more
doaj   +1 more source

Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy [PDF]

, 2013
Babafemi Taiwo, R. M. Matining, Lei Zheng, M. M. Lederman, C. R. Rinaldo, Peter S. Kim, B. I. Berzins, Daniel R. Kuritzkes, A. Jennings, Joseph J. Eron, C. C. Wilson   +10 more
openalex   +1 more source

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

Clinical Infectious Diseases, 2018
First-line raltegravir-containing combination antiretroviral therapy in 30 patients living with HIV-2 was well tolerated and yielded a median CD4 gain at 1 year of 87 cells/µL, and HIV-2 RNA
S. Matheron, D. Descamps, S. Gallien, A. Besseghir, P. Sellier, L. Blum, E. Mortier, C. Charpentier, R. Tubiana, F. Damond, G. Peytavin, D. Ponscarme, F. Collin, F. Brun-vezinet, G. Chêne, S F C L A E R P D L P J L M -A O B G P I F L Matheron Boue Goujard Weiss Rami Mortier Tubiana C, S. Matheron, F. Boué, C. Goujard, L. Weiss, A. Rami, E. Mortier, R. Tubiana, P. Campa, D. Ponscarme, L. Piroth, P. Miailhes, J. Reynes, L. Blum, M. Khuong, O. Patey, B. Elharrar, G. Beck-Wirth, P. Fialaire, I. Amri, F. Cardon, L. Marchand   +36 more
semanticscholar   +1 more source

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir [PDF]

, 2009
William D. Hanley, Larissa Wenning, Allison Moreau, James Kost, Eric Mangin, Trisha Shamp, Julie A. Stone, Keith Gottesdiener, John A. Wagner, Marian Iwamoto   +9 more
openalex   +1 more source

Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles [PDF]

, 2020
Sanya J. Thomas, Jacob T Kilgore, Bradford Becken, Coleen K. Cunningham, Amelia B. Thompson   +4 more
openalex   +1 more source

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1

Journal of Infectious Diseases, 2018
Background Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. Methods NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir
N. Stella-Ascariz, R. Montejano, J. Rodriguez-Centeno, B. Alejos, C. Schwimmer, J. Bernardino, B. Rodés, C. Allavena, C. Hoffmann, M. Gisslén, R. de Miguel, A. Esteban-Cantos, C. Wallet, F. Raffi, J. Arribas   +14 more
semanticscholar   +1 more source